Changing the way we do business

Recommendations to accelerate biomarker development in pancreatic cancer

Margaret A. Tempero, David Klimstra, Jordan Berlin, Tony Hollingsworth, Paula Kim, Nipun Merchant, Malcolm Moore, Doug Pleskow, Andrea Wang-Gillam, Andrew M. Lowy

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinoma is the most aggressive of all epithelial malignancies. In contrast to the favorable trends seen in most other common malignancies, the five-year survival of patients with this disease remains only 6%, a statistic that has changed minimally for decades. Only two drugs have been approved by the U.S. Food and Drug Administration (FDA) for use in pancreatic cancer in the last 15 years, and there are no established strategies for early detection.

Original languageEnglish (US)
Pages (from-to)538-540
Number of pages3
JournalClinical Cancer Research
Volume19
Issue number3
DOIs
StatePublished - Feb 1 2013
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Biomarkers
United States Food and Drug Administration
Neoplasms
Adenocarcinoma
Survival
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Changing the way we do business : Recommendations to accelerate biomarker development in pancreatic cancer. / Tempero, Margaret A.; Klimstra, David; Berlin, Jordan; Hollingsworth, Tony; Kim, Paula; Merchant, Nipun; Moore, Malcolm; Pleskow, Doug; Wang-Gillam, Andrea; Lowy, Andrew M.

In: Clinical Cancer Research, Vol. 19, No. 3, 01.02.2013, p. 538-540.

Research output: Contribution to journalArticle

Tempero, MA, Klimstra, D, Berlin, J, Hollingsworth, T, Kim, P, Merchant, N, Moore, M, Pleskow, D, Wang-Gillam, A & Lowy, AM 2013, 'Changing the way we do business: Recommendations to accelerate biomarker development in pancreatic cancer', Clinical Cancer Research, vol. 19, no. 3, pp. 538-540. https://doi.org/10.1158/1078-0432.CCR-12-2745
Tempero, Margaret A. ; Klimstra, David ; Berlin, Jordan ; Hollingsworth, Tony ; Kim, Paula ; Merchant, Nipun ; Moore, Malcolm ; Pleskow, Doug ; Wang-Gillam, Andrea ; Lowy, Andrew M. / Changing the way we do business : Recommendations to accelerate biomarker development in pancreatic cancer. In: Clinical Cancer Research. 2013 ; Vol. 19, No. 3. pp. 538-540.
@article{d078f425c58d4639a267cdb341b38226,
title = "Changing the way we do business: Recommendations to accelerate biomarker development in pancreatic cancer",
abstract = "Pancreatic ductal adenocarcinoma is the most aggressive of all epithelial malignancies. In contrast to the favorable trends seen in most other common malignancies, the five-year survival of patients with this disease remains only 6{\%}, a statistic that has changed minimally for decades. Only two drugs have been approved by the U.S. Food and Drug Administration (FDA) for use in pancreatic cancer in the last 15 years, and there are no established strategies for early detection.",
author = "Tempero, {Margaret A.} and David Klimstra and Jordan Berlin and Tony Hollingsworth and Paula Kim and Nipun Merchant and Malcolm Moore and Doug Pleskow and Andrea Wang-Gillam and Lowy, {Andrew M.}",
year = "2013",
month = "2",
day = "1",
doi = "10.1158/1078-0432.CCR-12-2745",
language = "English (US)",
volume = "19",
pages = "538--540",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Changing the way we do business

T2 - Recommendations to accelerate biomarker development in pancreatic cancer

AU - Tempero, Margaret A.

AU - Klimstra, David

AU - Berlin, Jordan

AU - Hollingsworth, Tony

AU - Kim, Paula

AU - Merchant, Nipun

AU - Moore, Malcolm

AU - Pleskow, Doug

AU - Wang-Gillam, Andrea

AU - Lowy, Andrew M.

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Pancreatic ductal adenocarcinoma is the most aggressive of all epithelial malignancies. In contrast to the favorable trends seen in most other common malignancies, the five-year survival of patients with this disease remains only 6%, a statistic that has changed minimally for decades. Only two drugs have been approved by the U.S. Food and Drug Administration (FDA) for use in pancreatic cancer in the last 15 years, and there are no established strategies for early detection.

AB - Pancreatic ductal adenocarcinoma is the most aggressive of all epithelial malignancies. In contrast to the favorable trends seen in most other common malignancies, the five-year survival of patients with this disease remains only 6%, a statistic that has changed minimally for decades. Only two drugs have been approved by the U.S. Food and Drug Administration (FDA) for use in pancreatic cancer in the last 15 years, and there are no established strategies for early detection.

UR - http://www.scopus.com/inward/record.url?scp=84873361771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873361771&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-12-2745

DO - 10.1158/1078-0432.CCR-12-2745

M3 - Article

VL - 19

SP - 538

EP - 540

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 3

ER -